Why can a patient have a myocardial infarction despite normal low‑density lipoprotein cholesterol and triglyceride levels?

Why Myocardial Infarction Occurs Despite Normal LDL and Triglycerides

A person can have a myocardial infarction despite normal LDL-C and triglyceride levels because standard lipid panels fail to capture critical atherogenic particles—specifically small dense LDL particles, low HDL cholesterol (especially HDL2 and HDL3 subfractions), elevated triglyceride-rich lipoprotein cholesterol (TRL-C), and lipoprotein(a)—all of which independently drive atherosclerotic cardiovascular disease risk.

The Limitation of Standard Lipid Measurements

Standard lipid panels measure total LDL-C concentration but do not assess LDL particle size or number. This is a critical blind spot:

• Small, dense LDL particles confer a threefold increased risk of myocardial infarction independent of total LDL-C levels 1
• These atherogenic particles are more easily oxidized and penetrate the arterial wall more readily than larger, buoyant LDL particles 1
• The predominance of small dense LDL is often accompanied by elevated triglycerides, increased VLDL and IDL, and decreased HDL-C—a metabolic cluster that drives coronary risk even when total LDL-C appears "normal" 1

HDL Cholesterol: The Protective Factor Often Overlooked

Low HDL cholesterol is a powerful independent risk factor that standard risk assessment may underemphasize:

• Both HDL2 and HDL3 subfractions are inversely associated with MI risk, with odds ratios of 0.17 and 0.29 respectively for the highest versus lowest quartiles 2
• A 1% decrease in HDL-C is associated with a 3–4% increase in coronary artery disease risk over 6 years—a stronger effect than LDL-C itself 3
• Even when total cholesterol is below 200 mg/dL, low HDL levels significantly increase MI rates in both men and women 3
• Apolipoproteins A-I and A-II (the protein components of HDL) provide additional predictive information beyond HDL-C levels and remain significantly associated with MI after adjustment for all other lipids 2

Triglyceride-Rich Lipoproteins and Residual Risk

Elevated triglyceride-rich lipoprotein cholesterol (TRL-C) independently predicts cardiovascular events:

• TRL-C is significantly associated with future MI (HR 3.05 for highest vs. lowest quartile) and peripheral artery disease (HR 2.58), independent of LDL-C and high-sensitivity CRP 4
• Nonfasting triglyceride levels are a strong independent predictor of MI, with men in the highest quintile having 2.5 times the risk of those in the lowest quintile 5
• This association is particularly pronounced when total cholesterol is also elevated, suggesting a multiplicative interaction 5
• Importantly, triglyceride levels remained significant predictors even after adjustment for LDL particle diameter, whereas LDL diameter lost significance after adjusting for triglycerides 5

The Interplay of Atherogenic Dyslipidemia

These lipid abnormalities cluster together in what is termed atherogenic dyslipidemia:

• Small dense LDL particles, elevated triglycerides, low HDL-C, and increased VLDL/IDL represent a metabolic trait that produces interrelated lipoprotein changes 1
• The TG/HDL ratio has been proposed as a marker, though recent evidence suggests HDL-C itself remains the more robust independent predictor of CAD prevalence and extent 6
• This metabolic pattern reflects underlying insulin resistance and is common in patients with metabolic syndrome, prediabetes, or type 2 diabetes—even when standard LDL-C and triglycerides fall within "normal" ranges

Additional Non-LDL Risk Factors

Beyond particle characteristics, other lipid-related factors contribute:

• Lipoprotein(a) [Lp(a)] is an independent genetic risk factor for ASCVD that is not captured by standard lipid panels; elevated Lp(a) patients may derive greater benefit from PCSK9 inhibitor therapy 7
• Apolipoprotein B (ApoB) reflects the total number of atherogenic particles (VLDL, IDL, LDL, Lp(a)) and may be elevated even when LDL-C is normal, particularly in patients with insulin resistance 8

Clinical Implications and Risk Stratification

For patients with MI despite "normal" lipids, advanced lipid testing should be considered:

• Measure HDL2 and HDL3 subfractions, apolipoprotein A-I and A-II 2
• Assess LDL particle size and number (via gradient gel electrophoresis or NMR spectroscopy) 1
• Quantify TRL-C and small dense LDL-C directly 4
• Check lipoprotein(a) levels 7, 8
• Consider apolipoprotein B as a marker of total atherogenic particle burden 8

Coronary artery calcium (CAC) scoring improves risk estimation beyond traditional risk factors and can inform medication allocation and LDL-C goals 7

Treatment Considerations

Even with "normal" baseline lipids, aggressive lipid management is warranted post-MI:

• High-intensity statin therapy (atorvastatin 40–80 mg or rosuvastatin 20–40 mg) should be initiated regardless of baseline lipid values in high-risk patients 9
• Target LDL-C <100 mg/dL in high CV risk patients; for very high-risk patients (including those post-MI), European guidance advocates for LDL-C <1.4 mmol/L (~54 mg/dL) 9, 10
• If LDL-C remains above target after 4–6 weeks of high-intensity statin, add ezetimibe 10 mg daily 9
• For persistent elevation, consider PCSK9 inhibitors (evolocumab or alirocumab) or bempedoic acid 11, 9
• For triglycerides 135–499 mg/dL, add icosapent ethyl 4 g/day as adjunct to statin therapy to lower cardiovascular risk 9
• Achieving both ≥50% LDL-C reduction AND an absolute LDL-C level <1.4 mmol/L after PCI provides optimal reduction in major adverse cardiac and cerebrovascular events 10

Common Pitfalls to Avoid

• Do not assume cardiovascular risk is low simply because standard LDL-C and triglycerides are within normal ranges—advanced lipid phenotyping may reveal high-risk particle patterns 1, 4
• Do not overlook low HDL-C as a powerful independent risk factor—it may be the dominant lipid abnormality driving risk in patients with "normal" LDL-C 2, 3
• Do not delay aggressive lipid-lowering therapy in post-MI patients based on baseline lipid levels—treatment targets are based on absolute risk, not baseline values 9, 10
• Do not rely solely on fasting lipid panels—nonfasting triglycerides are strong predictors of MI risk and may better reflect postprandial atherogenic lipoproteins 5